OGT Using Protein Array Platform to Develop Prostate Cancer Test, Plans Clinical Study
October 05, 2010
OGT Using Protein Array Platform to Develop Prostate Cancer Test, Plans Clinical Study
Oxford Gene Technology has identified a panel of biomarkers it claims can be used to distinguish individuals with prostate cancer from both normal individuals and those suffering from other diseases of the prostate.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Platform Comparison Study Favors Higher-Density Chromosomal Microarrays for AOH Detection
April 9, 2013 / BioArray News - OGT's Protein Array at Heart of Sengenics Deal, Test-Development Programs
March 19, 2013 / BioArray News - In Bid to Court Cancer Cyto Community, OGT Prepares CCMC-Designed Chip for Launch
February 26, 2013 / BioArray News - OGT Inks Deal with CCMC to Build Cancer Microarray
February 26, 2013 / GenomeWeb Daily News - OGT CEO Cites 'Exceptional Demand' for Cyto Chips in Decision to Establish US Office
November 27, 2012 / BioArray News